Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, is expanding its drug product manufacturing capabilities at its site in Guangzhou, China.   The new investment will fund the installation of an aseptic drug product fill and finish production line at the 17,000 square meter state-of-the-art cGMP mammalian facility. The Guangzhou facility began operations in the second quarter of 2021 and expects to deliver its first cGMP batch later this year.   The fill and f...